fashion -WSS

fashion

author：explore 2025-09-30 23:19:53 - browse：686

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： 6 phony surgeries that take placebo to the extreme

entertainment

Wikipedia

WSS

General Catalyst, Summa Health deal will turn on physician buy

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Cognito secures funding to test medical device for Alzheimer's

A solution to the after

Some dementia cases could be undiagnosed liver disease

A new nitrogen execution bill also undermines medical licensing

explore

fashion

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Medical records are filled with copy

Apple Vision Pro: A first look at health apps on the new VR headset

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Alabama hospital puts IVF treatments on hold

Malaria cases in Florida and Texas: Here’s what you need to know

Dario to buy mental health app maker Twill in cash and stock deal

knowledge

Covid misinformation case heads to Supreme Court

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Vertigo drug brings hope for rare neuron disorder, Niemann

A $475,000 price tag for a new cancer drug: crazy or meh?

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

entertainment

Wikipedia

focus